Low doses of L-DOPA and CPZ therapy for obsessive compulsive disorder

Low doses of L-DOPA and CPZ therapy for obsessive compulsive disorder - L-DOPA + CPZ therapy for OCD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000060895

Enrollment

Registered

2026-03-12

Start date

2024-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obsessive compulsive disorder

Interventions

LDOPA 150 mg and chlorpromazine 15 mg were administered to patients with obsessive-compulsive disorder.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with OCD according to DSM-5 and with a YBOCS score of 16 or higher. 2) Patients who have provided written consent to participate in the study. 3) Patients whose medications have not changed for at least three months.

Exclusion criteria

Exclusion criteria: Nothing in particular

Design outcomes

Primary

Measure	Time frame
YALE-BROWN OBSESSIVE-COMPULSIVE SCALE	—

Countries

Japan

Contacts

Public ContactShinichi Matsumoto

Osaka Neurological Institute Department of Neurology

dyt1mc@yahoo.co.jp06-6333-0080

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026